San Diego, California–(Newsfile Corp. – March 15, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – March 7, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – February 23, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – February 16, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – February 15, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – February 13, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Francisco, California–(Newsfile Corp. – February 2, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – January 31, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – January 27, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Phase 2 clinical trial planned to start in H1 2023 San Diego, California–(Newsfile Corp. – December 20, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or...